Pemetrexed and Cisplatin in Advanced Urothelial Carcinoma
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Pemetrexed has demonstrated a favorable response with minimal toxicity when used as single
agent as first-line and second-line treatment for advanced urothelial carcinoma. The response
rates were 32% and 28% for the first-line and second-line setting, respectively. Cisplatin is
one the most active chemotherapeutic agents in urothelial cancer, frequently used as
combination chemotherapy such as GP (gemcitabine plus cisplatin) or MVAC (methotrexate,
vinblastine, adriamycin, and cisplatin).
Pemetrexed and cisplatin showed favorable activity profile in advanced non-small cell lung
cancer with highly favorable toxicity profile.
This study is to assess the efficacy and safety of pemetrexed plus cisplatin in advanced
urothelial carcinoma.